GL 047296
Latest Information Update: 06 Feb 2005
Price :
$50 *
At a glance
- Originator Genelabs Technologies
- Class Antifungals; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Mycoses
Most Recent Events
- 18 Nov 2004 Discontinued - Preclinical for Mycoses in USA (unspecified route)
- 30 Jul 2002 Preclinical trials in Mycoses in USA (unspecified route)